Home » Stocks » Poseida Therapeutics

Poseida Therapeutics, Inc. (PSTX)

Stock Price: $12.83 USD 0.15 (1.18%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 793.10M
Revenue (ttm) n/a
Net Income (ttm) -86.53M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $12.83
Previous Close $12.68
Change ($) 0.15
Change (%) 1.18%
Day's Open 12.56
Day's Range 12.45 - 13.18
Day's Volume 225,484
52-Week Range 11.35 - 17.62

More Stats

Market Cap 793.10M
Enterprise Value 696.92M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding n/a
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -5.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -85.53M
Net Income -86.53M
Free Cash Flow -69.55M
Net Cash 96.18M
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC -217.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(131.25% upside)
Current: $12.83
Target: 29.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-85.53-41.99
Net Income-86.53-44.40
Shares Outstanding12.6212.18
Earnings Per Share-6.86-3.64
Operating Cash Flow-64.39-38.01
Capital Expenditures-5.16-1.28
Free Cash Flow-69.55-39.30
Cash & Equivalents12530.40
Total Debt29.1419.09
Net Cash / Debt96.1811.31
Book Value-150-76.72
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Poseida Therapeutics, Inc.
Country United States
Employees 149
CEO Eric M. Ostertag

Stock Information

Ticker Symbol PSTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PSTX
IPO Date July 10, 2020


Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.